Advertisement
Screener

VAXCYTE, INC. (PCVX) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

3.3 / 5 stars · 25/38 Roast Me

VAXCYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

VAXCYTE, INC. (PCVX) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $63.93 per share as of 2024-09-30, per its 10-Q filed 2024-11-05.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2024-11-05

  • 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $63.93.
  • 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $57.13.
  • 2024-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $55.31.
  • 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $38.93.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
2024-09-30$63.93
10-Q · filed 2024-11-05
2024-06-30$57.13
10-Q · filed 2024-08-06
2024-03-31$55.31
10-Q · filed 2024-05-08
2023-12-31$38.93
10-Q · filed 2024-11-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CRISPR Therapeutics AG (CRSP)$5.390B-11.68